SCHEMBL5086065

SCHEMBL5086065

C=CCNc1ncnc2c1ncn2C(CCOCP(=O)(O)O)COC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.38
RIN1 Q13671 1/20 0.38
CCNB2 O95067 8/20 0.36
CDK1 P06493 8/20 0.36
CCNB1 P14635 8/20 0.36
CCNB3 Q8WWL7 8/20 0.36
CDK2 P24941 2/20 0.36
DOT1L Q8TEK3 1/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HPRT1 P00492 1/20 0.35
FGFR1 P11362 1/20 0.34
SLC22A6 Q4U2R8 1/20 0.34
MAPK1 P28482 1/20 0.34
MAPK8 P45983 1/20 0.34
CSNK1A1 P48729 1/20 0.34
CSNK1D P48730 1/20 0.34
CDK7 P50613 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5083620 0.90 CCNB2 (0.39) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL5086381 0.87 DNPH1 (0.40) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL5080087 0.86 ABL1 (0.42) ABL1RIN1CCNB2CDK1CCNB1
SCHEMBL5086049 0.85 NT5E (0.38) ABL1RIN1DOT1LHPRT1FGFR1
SCHEMBL5083618 0.84 NT5E (0.40) ABL1RIN1NT5E
SCHEMBL5083530 0.84 NT5E (0.41) ABL1RIN1NT5E
SCHEMBL5085981 0.81 HPRT1 (0.37) SMN1; SMN2HPRT1FGFR1SLC22A6LMNA
SCHEMBL6055298 0.78 CCNB2 (0.34) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL6055289 0.77 CCNB2 (0.36) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL5086082 0.75 NPC1 (0.36) ABL1RIN1CCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7388002-B2 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2008-06-17 US disclosed
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases POLR2H, NSUN2, POLR2E ABL1 2347/4885RIN1 1635/4885CCNB2 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.